ACDN-01 results in robust, durable and well-tolerated ABCA4 exon editing in preclinical models
May 15, 2024
Ascidian Therapeutics Inc. recently provided preclinical data for ACDN-01, an AAV-encoded RNA exon editor targeting ABCA4, being developed for the treatment of ABCA4-related retinopathies, including Stargardt disease.
